Molecular Diagnostics Market: Market Size, Trends, and Forecast 2024-2032
The Molecular Diagnostics Market size was valued at USD 16.81 billion in 2023 and is expected to reach USD 37.70 billion by 2031, growing at a CAGR of 10.7% over the forecast period 2024–2031. This surge is driven by the growing need for faster, accurate, and cost-effective diagnostic techniques that are transforming the healthcare landscape globally.
Molecular diagnostics Market Size play a crucial role in identifying genetic mutations, infectious agents, and other biomarkers, making it a vital component of personalized medicine. The increasing demand for molecular diagnostics solutions is significantly influencing the market’s expansion, with widespread adoption in hospitals, research labs, and point-of-care testing.
Get Free Sample Report @ https://www.snsinsider.com/sample-request/2806
Key Players:
- Thermo Fisher Scientific (Applied Biosystems Real-Time PCR Systems, Ion Torrent Gene Sequencing Systems, TaqMan Real-Time PCR Assays)
- Roche Diagnostics (cobas 6800/8000 Systems, LightCycler 480 II Real-Time PCR System, Cobas AmpliPrep/Cobas TaqMan Assays)
- Illumina (NextSeq 500 System, NovaSeq 6000 System, MiSeq System)
- Agilent Technologies (SureSelect Target Enrichment Systems, SureSeq RNA Library Prep Kits, Agilent 2100 Bioanalyzer)
- Qiagen (QIAcube Automated RNA Extraction System, QIAseq RNA Library Prep Kits, Rotor-Gene Q Real-Time PCR System)
- Bio-Rad Laboratories (CFX Connect Real-Time PCR Detection System, S1000 Thermal Cycler, iCycler iQ Real-Time PCR Detection System)
- Beckman Coulter (DxI 8000 Chemistry System, DxI 6000 Chemistry System, Allegra X-22R Centrifuge)
- Seegene (Allplex COVID-19 Assay, Allplex Respiratory Panel, Allplex STI Panel)
- Cepheid (GeneXpert Systems, Xpert MTB/RIF Assay, Xpert HIV-1 RNA Assay)
- Abbott Laboratories (m2000 Real-Time PCR System, Alinity m Systems, RealTime PCR Assays)
- Oxford Nanopore Technologies (MinION System, GridION System)
- MGI Tech Co., Ltd. (DNBSEQ-T7 System, DNBSEQ-G400 System)
- BGI Group (GeneSeq Sequencers, BGISeq-500 System)
- NanoString Technologies (nCounter Analysis System, GeoMx Digital Spatial Profiler)
- Fluidigm Corporation (C1 Single-Cell Analysis System, BioMark HD System)
- Fujifilm Holdings (Lumio Molecular Imaging Systems)
- PerkinElmer (VICTOR Nivo Multimode Plate Reader)
- BioMérieux (NucliSENS EasyQ Real-Time PCR System)
- Siemens Healthineers (Versant Molecular Diagnostics Systems)
Key Points:
- Market size valued at USD 16.81 billion in 2023
- Projected to grow at a CAGR of 10.7% from 2024 to 2031
- Expected market size to reach USD 37.70 billion by 2031
- Rising cases of infectious diseases and cancer drive demand
- Growth of personalized medicine boosting market adoption
- Point-of-care and home diagnostics gaining popularity
- Advancements in PCR and sequencing technologies supporting innovation
- North America and Asia-Pacific identified as high-growth regions
Future Scope:
The future of the molecular diagnostics market looks promising as the integration of artificial intelligence, big data analytics, and next-generation sequencing continues to evolve. These technologies are expected to significantly enhance diagnostic accuracy and speed, leading to improved patient outcomes. Additionally, the increased focus on developing rapid diagnostic kits and the expansion of telemedicine services are likely to broaden the application and accessibility of molecular diagnostic tools across various healthcare settings worldwide.
Conclusion:
The molecular diagnostics market is undergoing rapid transformation, fueled by technological advances and rising global healthcare needs. As the industry continues to innovate and expand, it is poised to play a central role in shaping the future of diagnostic medicine. The market’s strong growth trajectory reflects its increasing importance in early disease detection, personalized treatment, and effective patient management.
Contact Us:
Jagney Dave - Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Other Related Reports:
Comments
0 comment